First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes - Chapter 4: Pre-clinical efficacy and complication data required to justify a clinical trial

Xenotransplantation

Volumn 23, Issue 1, 2016, Pages 46-52

  Cooper, David K C ^a   Bottino, Rita ^b   Gianello, Pierre ^c   Graham, Melanie ^d   Hawthorne, Wayne J ^e   Kirk, Allan D ^f   Korsgren, Olle ^g   Park, Chung Gyu ^h   Weber, Collin ⁱ  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b ALLEGHENY SINGER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UPPSALA UNIVERSITY   (Sweden)

^h Seoul National University   (South Korea)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

diabetes mellitus; islets; non human primates; pig xenotransplantation

Indexed keywords

GLUCOSE;

ALLOTRANSPLANTATION; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; CONSENSUS; GLUCOSE METABOLISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY ALLOGRAFT; MORBIDITY; MORTALITY; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PIG; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; XENOTRANSPLANTATION; ANIMAL; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; DIABETES MELLITUS, TYPE 1; INFORMED CONSENT; PROCEDURES; XENOGRAFT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; HUMANS; INFORMED CONSENT; ISLETS OF LANGERHANS TRANSPLANTATION; QUALITY OF LIFE; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84960798967     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12226     Document Type: Article

References (27)

1. World Health Organization. The Changsha Communique. First WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials Changsha, China, November 19-21, 2008.
2. Cooper DK,. Global consultation on regulatory requirements for xenotransplantation in clinical trials. Conference held in Changsha, China, November 19-21, 2008. Xenotransplantation 2009; 16: 58-60.
3. Hering BJ, Cooper DK, Cozzi E, et al., The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-executive summary. Xenotransplantation 2009; 16: 196-202.
4. Cooper DK, Casu A,. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-chapter 4: Pre-clinical efficacy and complication data required to justify a clinical trial. Xenotransplantation 2009; 16: 229-238.
5. Cooper DK, Bottino R, Satyananda V, et al., Toward clinical islet xenotransplantation-are revisions to the IXA guidelines warranted? Xenotransplantation 2013; 20: 68-74.
6. Samy KP, Martin BM, Turgeon NA, et al., Islet cell xenotransplantation: A serious look toward the clinic. Xenotransplantation 2014; 21: 221-229.
7. Van Der Windt DJ, Bottino R, Kumar G, et al., Clinical islet xenotransplantation: How close are we? Diabetes 2012; 61: 3046-3055.
8. Hawthorne WJ, Salvaris EJ, Phillips P, et al., Control of IBMIR in neonatal porcine islet xenotransplantation in baboons. Am J Transplant 2014; 14: 1300-1309.
9. Casu A, Bottino R, Balamurugan AN, et al., Metabolic aspects of pig-to-monkey (Macaca fascicularis) islet transplantation: Implications for translation into clinical practice. Diabetologia 2008; 51: 120-129.
10. Casu A, Echeverri GJ, Bottino R, et al., Insulin secretion and glucose metabolism in alpha 1,3-galactosyltransferase knock-out pigs compared to wild-type pigs. Xenotransplantation 2010; 17: 131-139.
11. Graham ML, Bellin MD, Papas KK, et al., Species incompatibilities in the pig-to-macaque islet xenotransplant model affect transplant outcome: A comparison with allotransplantation. Xenotransplantation 2011; 18: 328-342.
12. Graham ML, Schuurman HJ,. The usefulness and limitations of the diabetic macaque model in evaluating long-term porcine islet xenograft survival. Xenotransplantation 2013; 20: 5-17.
13. Wijkstrom M, Bottino R, Cooper DK,. Limitations of the pig-to-non-human primate islet transplantation model. Xenotransplantation 2013; 20: 2-4.
14. Mueller KR, Balamurugan AN, Cline GW, et al., Differences in glucose-stimulated insulin secretion in vitro of islets from human, nonhuman primate, and porcine origin. Xenotransplantation 2013; 20: 75-81.
15. Nagaraju S, Bertera S, Funair A, et al., Streptozotocin-associated lymphopenia in cynomolgus monkeys. Islets 2014; 6: E944441.
16. Luo B, Chan WF, Lord SJ, et al., Diabetes induces rapid suppression of adaptive immunity followed by homeostatic T-cell proliferation. Scand J Immunol 2007; 65: 22-31.
17. Bennet W, Sundberg B, Groth CG, et al., Incompatibility between human blood and isolated islets of Langerhans: A finding with implications for clinical intraportal islet transplantation? Diabetes 1999; 48: 1907-1914.
18. Bennet W, Sundberg B, Lundgren T, et al., Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: Protective effects of sCR1 and heparin [see comments]. Transplantation 2000; 69: 711-719.
19. Van Der Windt DJ, Bottino R, Casu A, et al., Rapid loss of intraportally transplanted islets: An overview of pathophysiology and preventive strategies. Xenotransplantation 2007; 14: 288-297.
20. Dufrane D, Goebbels RM, Gianello P,. Alginate macroencapsulation of pig islets allows correction of streptozotocin-induced diabetes in primates up to 6 months without immunosuppression. Transplantation 2010; 90: 1054-1062.
21. Veriter S, Gianello P, Igarashi Y, et al., Improvement of subcutaneous bioartificial pancreas vascularization and function by coencapsulation of pig islets and mesenchymal stem cells in primates. Cell Transplant 2014; 23: 1349-1364.
22. Sgroi A, Buhler LH, Morel P, et al., International human xenotransplantation inventory. Transplantation 2010; 90: 597-603.
23. Elliott RB,. Towards xenotransplantation of pig islets in the clinic. Curr Opin Organ Transplant 2011; 16: 195-200.
24. Wynyard S, Nathu D, Garkavenko O, et al., Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand. Xenotransplantation 2014; 21: 309-323.
25. U.S. Department of Health and Human Services, Food and Drug Administration (CBER). Guidance for industry: Source animal, product, preclinical and clinical issues concerning the use of xenotransplantation products in humans. Available at: Http://www.fda.gov/cber/gdins/clinxeno.htm, 2003, [accessed on April 2003]
26. Cardona K, Korbutt GS, Milas Z, et al., Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med 2006; 12: 304-306.
27. Hecht G, Eventov-Friedman S, Rosen C, et al., Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate model. Proc Natl Acad Sci U S A 2009; 106: 8659-8664.